Horizon Healthcare Services, Inc., New Jersey’s largest and oldest health insurer, has agreed to provide reimbursement for Kimberly-Clark’s SIngergy Cooled Radiofrequency System. The policy covers sacroiliac joint denervation for patients diagnosed with chronic sacroiliac joint (SIJ) pain. The procedure temporarily destroys the nerve endings to the sacroiliac joint.
A Kimberly-Clark press release stated that approximately four out of five adults in the U.S. will experience chronic axial low back pain, and SIJ pain accounts for between 18% and 30% of that. This number, claims the company, converts to Americans spending at least $50 billion each year on low back pain, making it the most common cause of job-related disability and a leading contributor to missed work.
The procedure is a minimally-invasive treatment intended to target and treat the pain-generating nerves in the lower back and buttock region that may be responsible for SIJ pain. The treatment can significantly reduce low back pain, according to the company.
Additionally, the company says results of a study published in the March edition of Pain Medicine showed that slightly more than half of patients treated with the procedure demonstrated significant improvements in pain, disability and quality of life outcomes. The durability of the relief was also maintained at the nine-month follow-up.
The Pain Medicine study compared lateral branch neurotomy using cooled radiofrequency to a sham intervention. Lateral branch neurotomy involved the use of cooled radiofrequency electrodes to ablate the S1–S3 lateral branches and the L5 dorsal ramus. The sham procedure was identical to the active treatment, except that radiofrequency energy was not delivered.
Study authors, Nilesh Patel M.D., Andrew Gross M.D., Lora Brown M.D. and Gennady Gekht M.D., reported statistically significant changes in pain, physical function, disability, and quality of life were found at three-month follow-up, with all changes favoring the lateral branch neurotomy group. At three-month follow-up, 47% of treated patients and 12% of sham subjects achieved treatment success. At six and nine months, respectively, 38% and 59% of treated subjects achieved treatment success.
